NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 319 filers reported holding NOVOCURE LTD in Q3 2021. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,318,557 | -62.7% | 1,258,115 | -4.1% | 0.04% | -65.0% |
| Q2 2023 | $54,439,949 | +114.0% | 1,311,806 | +210.1% | 0.12% | +87.5% |
| Q1 2023 | $25,440,965 | +1438.1% | 423,029 | +1677.4% | 0.06% | +1180.0% |
| Q2 2022 | $1,654,000 | -67.5% | 23,800 | -61.2% | 0.01% | -68.8% |
| Q1 2022 | $5,087,000 | -10.8% | 61,393 | -19.2% | 0.02% | -20.0% |
| Q4 2021 | $5,704,000 | +425.2% | 75,966 | +712.3% | 0.02% | +300.0% |
| Q3 2021 | $1,086,000 | -87.9% | 9,352 | -88.4% | 0.01% | -92.4% |
| Q3 2020 | $8,970,000 | -58.1% | 80,588 | -77.7% | 0.07% | -64.5% |
| Q2 2020 | $21,411,000 | +1572.7% | 361,055 | +1684.2% | 0.19% | +2225.0% |
| Q2 2019 | $1,280,000 | +140.6% | 20,236 | +83.2% | 0.01% | +100.0% |
| Q1 2019 | $532,000 | +10.8% | 11,047 | +20.5% | 0.00% | +100.0% |
| Q3 2018 | $480,000 | -24.2% | 9,165 | -68.4% | 0.00% | -33.3% |
| Q1 2018 | $633,000 | – | 29,036 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |